ClinicalTrials.gg
Enrolling by invitationNCT06944353STIRREDUpdated May 29, 2026

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

An interventional study of STIRRED in Non-Alcoholic Fatty Liver Disease, Steatosis of Liver and Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by Northwestern University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Northwestern University · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,704
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Planned enrollment
2nd of 460
4,704 · median 56
Started
2025
with 15 others
No phase
128 of 547
16 open now
Primary completion
2027-01
later than 37 of 92 live
Registered
532nd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 2nd largest by planned enrollment of the 460 interventional ones that give a count, is one of 16 that started in 2025, is one of 128 with no phase, reaches primary completion later than 37 of the 92 other live ones, and was the 532nd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning and natural language processing that will prompt reporting to patients and provide ED clinicians risk stratified follow-up care recommendations. Data on both the implementation and effectiveness of our intervention resulting from this trial will inform future use with a goal of ultimately improving diagnostic safety and outcomes for patients with hepatic steatosis.

Read the detailed description

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a public health crisis affecting one third of the US adult population. Steatotic liver disease is an obesity related disease with serious health and quality of life consequences. Hepatic steatosis is reported on \~10% of written radiology reports. Unfortunately, lack of awareness often leads to hepatic steatosis being overlooked by providers and unreported to patients leading to delays in diagnosis and referral to specialty care.

This project, Improving Diagnostic Safety through STeatosis Identification, Risk stratification, and Referral pathway in the ED (STIRRED), proposes to improve diagnostic safety by ensuring that patients receive timely notification of the new finding and referral to follow up care. The STIRRED CDSS intervention employs natural language processing and machine learning to identify hepatic steatosis in written emergency department (ED) radiology reports and combine it with common clinical data in the electronic health record to create an individualized risk profile and follow up recommendations for patients with suspected MASLD. This recommendation is communicated to the ED clinician during the ED discharge process via an OurPractice Advisory (OPA) and triggering outpatient referral for follow-up care stratified by risk level.

This trial will evaluate STIRRED across a large health system using a type 2 implementation-effectiveness stepped wedge cluster randomized trial across 11 Emergency Departments in a single health system. Effectiveness of providing risk-based care linkage and implementation outcomes will be evaluated.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Steatosis of Liver
  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Keywords

  • Metabolic Associated Steatotic Liver Disease
  • Incidental Radiology finding
  • Emergency Medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • imaging finding of hepatic steatosis on ED imaging study
  • discharged from the ED to home
  • first Northwestern Medicine ED visit in the study period with a hepatic steatosis finding

Exclusion criteria

Exclusion Criteria:

  • admitted to the hospital
  • age \< 18
  • pre-existing Liver Disease diagnosis (Liver Cancer, , , Cirrhosis, NAFLD/MASLD/NASH/MASH, Alcohol Liver Disease, PSC, PBC and hepatitis)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,704 participants (estimated)

Study arms

  • No intervention
    Usual Care

    Includes any patient notification about steatosis, education and referrals as per the treating clinician's usual and customary practice.

  • Experimental
    STIRRED

    Patients with incidentally noted hepatic steatosis who are seen in Emergency Departments after STIRRED intervention has been activated within the local EHR may receive additional notification about steatosis, education or referrals for additional testing and follow-up as prompted by the STIRRED intervention which is directed at their discharging clinician.

    Behavioral: STIRRED

Interventions

  • BehavioralSTIRRED

    The STIRRED intervention is a behavioral intervention directed at the treating ED clinicians. An Our Practice Advisory (OPA) will alert the clinician to the radiology finding of hepatic steatosis at the time of preparing the discharge materials. The OPA will prompt the clinician to discuss this finding with the patient and will automatically add hepatic steatosis to the discharge diagnoses and insert patient-facing discharge information about hepatic steatosis. It will additionally prompt the clinician to refer the patient for follow-up which will be stratified based on their fibrosis risk level.

06

What researchers measure

Primary outcomes

  1. Effectiveness: New steatotic liver disease-related diagnosis among high-risk patients

    For patients at high risk for liver fibrosis, The investigators will evaluate for new steatotic liver disease related ICD codes.

    Time frame: 120 days post-ED discharge

  2. Implementation: Intervention fidelity

    Fidelity is the degree to which the STIRRED CDSS was delivered as intended. Fidelity will be evaluated across four components: 1. hepatic steatosis added to the ED discharge diagnoses; 2. hepatic steatosis patient education provided; 3. ED adoption of confirming that the clinicians have informed the patient of the new finding; and 4. ED adoption of placing referral and/or recommendation for follow-up (distinct from routing the message to PCP). The Investigators will analyze individual components and a composite score of 0-4 that combines these outcomes. The fidelity components and their composite score (0-4) will be audited monthly from 3 months prior to implementation to 3 months after implementation.

    Time frame: Baseline at time of intervention delivery

Other outcomes

  1. Effectiveness: New steatotic liver disease-related diagnosis among all patients

    For all patients with incidentally discovered hepatic steatosis, the investigators will evaluate for new steatotic liver disease related ICD codes.

    Time frame: 120 days post-ED discharge, 1 year post-ED discharge

  2. Effectiveness: Non-invasive testing (NIT) completion

    completion of a fibroscan, liver ultrasound, liver elastography, MRI abdomen, MR Elastography or Enhanced Liver Fibrosis(ELF) that indicate ongoing diagnostic process

    Time frame: 1 year post-ED discharge

  3. Effectiveness: new liver lab test completion

    Completion of three key liver disease related lab tests (Liver Function tests, Hepatitis serologies \[Hepatitis C Antibody, Hepatitis B surface antigen, Hepatitis B Core antibody, Hepatitis B surface antibody\] and INR level) that indicate ongoing diagnostic process;

    Time frame: 1 year post-ED discharge

  4. Effectiveness: new medication initiation

    Receipt of a new prescription for a medication known to impact steatotic liver disease outcomes (e.g., pioglitazone, vitamin E, GLP1 agonist, SGLT2 inhibitor) as an indicator of engagement in lifestyle changes and weight loss interventions.

    Time frame: 1 year post-ED discharge

  5. Effectiveness: new referrals

    Receipt of referral to lifestyle medicine (nutrition) or bariatric surgery as an indicator of engagement in lifestyle changes and weight loss interventions.

    Time frame: 1 year post-ED discharge

  6. Effectiveness: weight change

    Weight values for patients will be evaluated when available to assess for weight loss over time as an indicator of engagement in lifestyle changes and weight loss interventions.

    Time frame: 1 year post-ED discharge

  7. Implementation: Acceptability of Intervention Measure (AIM)

    Acceptability is the perception that STIRRED is satisfactory or agreeable to ED clinicians

    Time frame: 2 months after STIRRED implementation; 4 months after final site STIRRED implementation

  8. Implementation: Intervention Appropriateness Measure (IAM)

    Appropriateness is the perceived fit or compatibility of STIRRED for the ED and ED patients

    Time frame: 2 months after STIRRED implementation; 4 months after final site STIRRED implementation

  9. Implementation: Feasibility of Intervention Measure (FIM)

    feasibility is the extent to which STIRRED can be used within the course of an ED clinical encounter

    Time frame: 2 months after STIRRED implementation; 4 months after final site STIRRED implementation

  10. Implementation: Clinical Sustainability

    The Clinical Sustainability Assessment Tool (CSAT) will be used to understand factors that contribute to sustainability of the STIRRED model in practice over time from the perspective of the ED clinicians.

    Time frame: 2 months after STIRRED implementation; 4 months after final site STIRRED implementation

  11. Implementation: Cognitive Load of Intervention

    NASA task load index (TLX) will assess cognitive load of STIRRED for the ED clinicians. The NASA TLX is a 6-item instrument that has been used to measure the workload of a system.

    Time frame: 2 months after STIRRED implementation; 4 months after final site STIRRED implementation

07

Study locations

1 site
08

References and documents

Publications

  • McCarthy DM, VanWagner LB, Rafferty MR, Cameron KA, Lee J, Dong S, Fellner A, Kontrick AV. Improving diagnostic safety through STeatosis Identification, Risk stratification, and Referral pathway in the ED (STIRRED): Protocol for an effectiveness implementation trial. Contemp Clin Trials. 2026 Feb;161:108187. doi: 10.1016/j.cct.2025.108187. Epub 2025 Dec 15. PubMed 41407098 ↗

Individual participant data

Plan to share: Yes — De-identified IPD used in the analysis of the hybrid implementation effectiveness trial will be shared. All published data will be formatted according to the principals of Common Data Elements (CDE) as defined by the NIH. Clinical and survey response data will contain raw item responses as well as any aggregate scores for participants. To facilitate future use and interoperability of our data, we will employ standard processing and documentation protocols adopted by the Inter-university Consortium for Political and Social Research (ICPSR) for data formats and dictionaries as well as for variable names, descriptions, and labels. Data will be made available through a data repository (still to be determined) following the completion of the grant period and final publication of the trial manuscript.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 13 months is below that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 25, 2025
StartActual
Dec 4, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2028
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06944353
Collaborators
Agency for Healthcare Research and Quality (AHRQ), University of Texas, Southwestern Medical Center at Dallas
Responsible party
Amy Kontrick (Associate Professor, Northwestern University) — Principal investigator
First posted
Apr 25, 2025
Start date
Dec 4, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
May 29, 2026

Study contacts

Amy V Kontrick, MD
principal investigator · Northwestern University
Danielle M McCarthy, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion